C1QA and diffuse large B-cell lymphoma: Studies have shown that METTL3 inhibits the complement pathway by mediating C1qA methylation and enhances resistance to Rituximab, thereby facilitating the progression of diffuse large B-cell lymphoma (DLBCL) [286].